Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC.
Non-squamous Non-small-cell Lung Cancer
DRUG: Tiragolumab|DRUG: Atezolizumab|DRUG: Bevacizumab
Objective Response Rate (ORR), As defined by investigator-assessed ORR according to RECIST v1.1, Up to end of treatment (average 9 months)
Incidence of Treatment-Related Adverse Events, Incidence and severity of adverse events, with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0), At the end of each cycle of therapy (every ~21 days)|Progression Free Survival (PFS), Up to 5 years|6-month PFS rate, Up to 5 years|Duration of Response (DOR), Up to 5 years|Overall Survival (OS), Up to 5 years
To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC.